⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,720
Total Claims
$4.9M
Drug Cost
1,015
Beneficiaries
$4,873
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+24%
Cost per patient vs peers
$4,873 vs $3,933 avg
Brand vs Generic
49% generic
Brand: 4,079 claims · $4.7M
Generic: 3,867 claims · $112K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 430 | $659K |
| Insulin Aspart | 264 | $401K |
| Insulin Lispro | 274 | $397K |
| Semaglutide | 179 | $324K |
| Insulin Glargine,hum.Rec.Anlog | 299 | $314K |
| Dapagliflozin Propanediol | 194 | $283K |
| Dulaglutide | 110 | $253K |
| Insulin Glargine/Lixisenatide | 140 | $248K |
| Exenatide Microspheres | 72 | $145K |
| Semaglutide | 52 | $129K |
| Insulin Glargine,hum.Rec.Anlog | 121 | $119K |
| Insulin Glargine,hum.Rec.Anlog | 49 | $116K |
| Insulin Lispro | 65 | $90K |
| Insulin Aspart | 46 | $84K |
| Insulin Glargine,hum.Rec.Anlog | 112 | $73K |
Prescribing Profile
Patient Profile
74
Avg Age
58%
Female
1.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About